Clinical Trial Search

Primary: Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 129; 31…

Primary: Number of Participants With Treatment-emergent Adverse Events — 3; 4; 5; 5 Participants

Primary: Number of Subjects Reporting Adverse Events (AEs) and Dose-limiting Toxicities (DLTs) — 11; 11; 0; 0 Participants

Primary: Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 — 149.0; NA; NA; 310.6 nanograms per milliliter (ng/mL)

Primary: Change From Baseline in Asthma Control Questionnaire (ACQ) Composite Scores to Week 12 — -0.427; -0.521; -0.512; -0.556 Score on a scale — p=0.5838

Primary: Difference in Z-score for Rank of Maximum Transverse Diameter (MTD) Regressed on Z-score at Baseline to Assess Growth in Abdominal Aortic Aneurysm MTD Determined by CT…

Primary: Hemodynamic Effect as Measured by Systolic Blood Pressure Before and After RSI — 138.04; 132.39; 139.09; 130.09 mmHg

Primary: Percentage of Evaluable Participants Achieving Progression-Free Survival (PFS) at 3 Months — 81.8 percentage of participants

Primary: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma — 0.93; 2.10 events per year — p=<0.001

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) — 67; 5; 7; 0 Participants

Primary: Change in Patient Global Impression of Change — 53.1; 51.5 score on a scale

Primary: Intraoperative Pneumoperitoneal Pressure (mmHg) — 7.9; 9.9 mmHg — p=<0.001

Primary: Boston Naming Test — 10.3; 37.7 percent change from baseline

Primary: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 — 33.5; 4.1 percentage of participants — p=<0.001

Primary: Number of Adverse Events Reported — 58; 444; 8 Events